Plain-English translation of NCT07524114 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →The SHERLOCK study uses blood tests to look for circulating tumor DNA—tiny fragments of cancer that may remain after you've completed cancer treatment. Researchers are testing whether this sensitive blood test can catch cancer recurrence earlier than standard imaging, potentially allowing for earlier intervention if needed.
Current imaging methods may not always catch cancer early enough after treatment ends. This trial aims to see whether blood tests can detect cancer's early warning signs sooner, giving doctors a chance to act faster if cancer begins to return.
You likely qualify if…
You likely don't qualify if…
You will have blood samples drawn regularly to test for circulating tumor DNA. You'll also continue with standard imaging scans (like CT or MRI) to compare the blood test results with what imaging shows. If your blood test suggests minimal residual disease, you may be offered the option to join additional treatment trials, but that would be separate from this study. The study will track your outcomes over time to see how well the blood test predicts who might have cancer recurrence.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
Canada